Drugs / IMOJEV
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00621764 | Mar 2008 → Dec 2009 | Japanese encephalitis, hepatitis A virus infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMOJEV | “The live-attenuated Japanese encephalitis (JE) vaccine (JE-CV; IMOJEV) induces a protective response in children.” PMID 27815383 ↗ Jan 2017 |
| Known as | JE-CV | “A live-attenuated JE-chimeric virus vaccine (JE-CV) has been developed with a single-dose regimen.” PMID 20856164 ↗ Dec 2010 |
| Modality | Vaccine | “A live-attenuated JE-chimeric virus vaccine (JE-CV) has been developed with a single-dose regimen.” PMID 20856164 ↗ Dec 2010 |
| Route | Subcutaneous | “≥4.0 Log10 PFU SC (Day 28)” NCT00621764 ↗ |